(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S.

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

Walt Disney ( DIS) will release its results on Wednesday, with attention on its media networks, theme parks, and streaming services. Analysts expect earnings of $1.47 per share and $23.7bn in revenue, ...

In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Tempus AI TEM and NVIDIA NVDA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing ...

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.